Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.
about
Advances in the development of new biologics in inflammatory bowel diseaseUstekinumab for the treatment of Crohn's disease: can it find its niche?Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapyUstekinumab in Crohn's disease: evidence to date and place in therapyUstekinumab for the treatment of Crohn's disease.Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature.Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic RiskImmunopathogenesis of granulomas in chronic autoinflammatory diseases.New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.Top-down approach to biological therapy of Crohn's disease.Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.Ustekinumab: a novel therapeutic option in Crohn's disease.Next-Generation Therapeutics for Inflammatory Bowel Disease.IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know.Ustekinumab: A Review in Moderate to Severe Crohn's Disease.Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.Ustekinumab use in Crohn's disease: a Canadian tertiary care centre experience.Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.Clinical utility of ustekinumab in Crohn's disease.Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
P2860
Q26745782-385ABFF6-ECDF-4D9A-919B-293E8CFB4715Q26771890-9CA1EA44-AB23-4325-8C96-8719DE1FC95CQ28067631-7CEBC0E5-EB4F-4098-B899-8C8F5C28A14AQ28073787-42872DD0-3B3C-448B-84B4-6F81877ED84BQ30390909-38E62B5B-C049-43AB-BCC0-FE8772F25F98Q33815262-5A3E3B2B-5CB9-4D6A-A896-0E5F9FA5C58FQ36128550-C725875F-8F0C-4153-9B52-C0F109004DD6Q37538526-D9E8769E-D4C8-4A99-8BBE-BB97A4E6DC37Q38293802-7FD39976-0BC4-457E-8093-DEAD1E910088Q38549995-3C742604-0EA7-4F9E-867F-5A02830CAD50Q38692257-9E292023-26C8-4E25-9E3A-6205241A8EFEQ38748380-252E2B43-B1E8-4353-9A68-C462A04B95C3Q38749257-DB7D3F8F-E23B-4EEA-9D11-CE4E87EB8F03Q38764671-75294C4D-59D5-4B3C-B0EE-E4BF5171D7B3Q38798137-6E9C0A8E-395B-4516-9F3C-9D7FC297FAA8Q38875961-EE6AF424-0601-4F73-BF4E-1FEB0FE507A2Q38909523-E050FDBF-9498-4FAF-842D-5ADF14046120Q39032463-CBEA5A8A-74C9-4EC9-A551-8B12E35C44C8Q39048706-873D2989-7637-449D-9E47-1FDFCD169D56Q39140194-09A5256C-3B2A-4701-AAB2-0C25D7676E85Q39320474-510DE5F6-3CB1-4594-B050-268B979BAB79Q47141159-559CC52A-81C4-4218-B96D-0E125C24FA1EQ48014899-63723134-6807-472A-ACF3-747252D70EF4Q48172992-FA399670-57C6-4B74-8975-2FE70DFEBC94Q48267364-F8C40883-3676-44B9-AD04-2BF9A679E5C7Q48282663-00EEA422-33BD-435F-A4F9-2CABE7B1E437Q49218809-358C633F-1A81-4EED-B010-4BFBDFCC4A7BQ50012048-78F93FE6-3EB1-4BF5-B26E-75359304DBC9Q50237402-1B397E71-05E7-44CD-BED5-643634561228Q50782815-0FCCA8E9-F88C-4562-8F29-1E4D58CCE166Q55026569-9ED77C80-DAB5-4034-B73E-FF5B19831571
P2860
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Subcutaneous ustekinumab for t ...... isease--the McGill experience.
@en
Subcutaneous ustekinumab for t ...... isease--the McGill experience.
@nl
type
label
Subcutaneous ustekinumab for t ...... isease--the McGill experience.
@en
Subcutaneous ustekinumab for t ...... isease--the McGill experience.
@nl
prefLabel
Subcutaneous ustekinumab for t ...... isease--the McGill experience.
@en
Subcutaneous ustekinumab for t ...... isease--the McGill experience.
@nl
P2093
P2860
P1476
Subcutaneous ustekinumab for t ...... isease--the McGill experience.
@en
P2093
A Szilagyi
T Al-Taweel
T Bessissow
P2860
P304
P356
10.1016/J.CROHNS.2014.06.005
P50
P577
2014-07-01T00:00:00Z